Background: National guidelines endorse time-dependent quality metrics for breast cancer care. We examined factors associated with delays in chemotherapy initiation at an NCI-Designated Comprehensive Cancer Center. Patients and Methods: We identified 523 patients who received postoperative adjuvant chemotherapy between January 2011 and December 2013 at our center. We defined 28 days from last definitive surgery (LDS) to chemotherapy as the target time frame, and an unacceptable delay in chemotherapy initiation (UCD) as greater than 42 days from LDS. Multivariate regression models were used to identify factors associated with UCD and the impact of Oncotype DX testing in patients with hormone receptor (HR)-positive breast cancer. Results: Median days between LDS and chemotherapy initiation was 34 (interquartile range, 15), with 30% of patients starting within 28 days of LDS and 26.9% having UCD. Tumor characteristics such as subtype and stage affected UCD; patients with HR-positive or HER2-positive tumors were more likely to be delayed compared with those with triple-negative breast cancer. Patients with stage I disease, those undergoing mastectomy with or without immediate reconstruction, and those whose pathology sign-out was greater than 10 days postoperatively were more likely to be delayed. A higher proportion of UCD was found in HR-positive patients (31%) for whom Oncotype DX testing was ordered compared with those in whom it was not ordered (20%).
Factors Associated With Delays in Chemotherapy

Background
Over the past 50 years, substantial reductions in early breast cancer mortality have been documented due to a combination of earlier detection and to advances in adjuvant treatment. [1] [2] [3] [4] In particular, adjuvant chemotherapy has been shown to decrease the risk of breast cancer recurrence, with an estimated relative risk reduction of up to 30% to 50%. 5, 6 The benefit of adjuvant chemotherapy may partly depend on the timing of therapy initiation. Recent studies suggest that delays in adjuvant chemotherapy initiation greater than 49 to 90 days after surgery may be associated with inferior outcomes, particularly among patients with triple-negative breast cancer (TNBC), HER2-positive subtypes, and higher-stage tumors. [7] [8] [9] [10] [11] [12] A meta-analysis conducted by Yu et al 13 suggested that overall survival decreases by 15% for every 4-week delay in chemotherapy initiation. Although these retrospective data must be interpreted carefully given potential confounders and selection bias, from a patient-centered perspective, delays to chemotherapy initiation also can adversely impact patient satisfaction and increase stress and anxiety.
Limited knowledge exists on processes of care within institutional and physician control, which influence the timing of chemotherapy initiation. These processes include referral from surgery to medical oncology, postoperative appointment scheduling, pathology turnaround time, and the role of additional testing, such as Oncotype DX (Genomic Health, Redwood City, CA). In this study, we sought to elucidate factors associated with delays in chemotherapy initiation after last definitive surgery (LDS), and to characterize the role of these factors on the treatment timeline for patients treated at our comprehensive cancer center.
Patients and Methods
Setting
We examined the care of women treated for breast cancer at the Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), a Harvard-affiliated NCI-Designated Comprehensive Cancer Center. The breast cancer program is organized as a multidisciplinary disease center. With more than 3,000 new patients annually, the DF/BWCC breast cancer program involves 28 medical, 12 surgical, and 4 radiation oncologists.
Data Source
We developed an internal dataset of patients treated for breast cancer at our institution through the integration of administrative and billing databases from the Brigham and Women's Hospital and the Dana-Farber Cancer Institute.
14 Using ICD-9 and CPT codes from surgical billing data, women with breast cancer who underwent lumpectomy, mastectomy, or mastectomy with immediate reconstruction (MIR) at our 2 primary surgical sites between January 2011 and December 2013 were identified. Using unique patient identifiers, we extracted all adjuvant chemotherapy administered to this surgical cohort through our chemotherapy order entry system. This initiative was undertaken as a quality improvement project and was determined to be exempt from review by the Dana-Farber/Harvard Cancer Center Institutional Review Board.
Study Cohort
We identified a cohort of 523 women with invasive stage I-III breast cancer who underwent surgery at 1 of 2 surgical sites and initiated adjuvant chemotherapy between January 2011 and December 2013. Patients who received neoadjuvant or investigational therapy or preoperative radiation therapy, patients with stage IV disease, and male patients were excluded.
Outcome Measures
Our primary outcome of interest was the interval between LDS to chemotherapy initiation. LDS was defined as the date of the breast surgical procedure immediately before chemotherapy initiation. Through a multidisciplinary consensus process, a team of medical, surgical, and radiation oncologists determined that the target for initiation of chemotherapy should be 28 or fewer days from LDS, and the unacceptable delay to chemotherapy initiation (UCD) should be 42 or more days from LDS, to ensure the optimal patient care experience. The target of 28 or fewer days was used to distinguish timely from delayed care in our subsequent analyses. Wait times to chemotherapy initiation were grouped as follows: 28 or fewer days, 29 to 41 days, and 42 or more days.
Covariates
Covariates of interest were: race (white vs nonwhite), age at LDS (<40, 40-49, 50-59, 60-69, ≥70 years), insurance (private vs public), year of surgery (2011, 2012, 2013) Pathology sign-out more than 10 days from LDS was considered "delayed."
The aggregated data set included the following variables: LDS date, LDS procedure type, date of postoperative medical oncology appointment, adjuvant chemotherapy start date, and patient sociodemographic characteristics. Medical chart reviews were conducted to extract information on pathology sign-out date, pathologic stage, tumor grade, tumor subtype, and use of Oncotype DX testing.
Statistical Analysis
Descriptive statistics were generated on the time from LDS to chemotherapy initiation. A series of multivariate multinomial logistic regressions were performed to evaluate predictors of timely chemotherapy initiation. In these models, we compared the likelihood of waiting 29 to 41 days to initiate chemotherapy versus starting 28 or fewer days after LDS, and the probability of waiting 42 or more days versus initiating chemotherapy at 28 or fewer days after LDS. In the first model we examined factors associated with delay, including patient age, race, insurance, year of surgery, stage, tumor subtype, LDS procedure, and pathology turnaround time. In the second model we examined predictors of timely chemotherapy initiation for patients with hormone receptor (HR)-positive/HER2-negative disease. In this model, we assessed for all factors included in the first model with the addition of whether Oncotype DX testing was performed. Models focused on TNBC and HER2-positive disease were not performed due to smaller patient populations. In our third model, we assessed factors associated with timely chemotherapy in patients with stage II and III disease. Factors included in this model were consistent with the first model. Patients who initiated chemotherapy 28 or fewer days after LDS served as the reference cohort for all 3 models. Adjusted odds ratios (ORs), 95% confidence intervals (CIs), and P values were calculated to ascertain the strength of the association between each variable and delayed care. For patients who initiated chemotherapy 42 or more days from LDS, chart reviews were conducted to determine the presence of additional factors, including postoperative surgical complications, consideration of clinical trial enrollment, and patient-driven decision-making.
Results
Cohort Characteristics
We identified 523 women with stage I-III breast cancer who initiated chemotherapy between 2011 and 2013 after breast surgery at DF/BWCC. The mean age was 51.1 years; 81.1% were white; 95.2% were English-speaking; and 80.1% had private insurance. Approximately half of the patients underwent lumpectomy (50.7%), 17.0% had mastectomy alone, and 32.3% underwent MIR. Patient and tumor characteristics are listed in Table 1 .
Time From LDS to Chemotherapy
Overall, the median time to initiate chemotherapy was 34.0 days (interquartile range [IQR], 15.0), ranging from 6 to 132 days ( Figure 1 ). Among these patients, 30.5% initiated chemotherapy within 28 days of LDS, 42.4% initiated chemotherapy between 29 and 41 days, and 26.9% experienced UCD.
Multivariate multinomial analysis in Table 2 Finally, when we restricted the analyses for patients with more advanced disease (stage II or III), the only factor that remained significant was surgical procedure (Table 4) . Patients who underwent MIR (MIR vs lumpectomy: OR, 3.87; 95 CI, 1.76-8.49) were significantly more likely to experience UCD compared with those undergoing lumpectomy.
Reasons for UCD
Among the 141 patients who experienced UCD, 23 had postoperative wound complications and 12 were considering a clinical trial. Other reasons for UCD included family events, comorbidities, and patient deci-sion-making. In half of the patients (n=71), we were not able to ascertain any additional factors that may have played a role in delaying chemotherapy initiation.
Discussion
Within a cohort of more than 500 consecutive women with breast cancer treated with adjuvant chemotherapy, the median number of days between LDS and chemotherapy initiation was 34, with most patients initiating treatment within 6 weeks of LDS. However, 26.9% of patients experienced an unacceptable delay, as defined prospectively by our breast cancer clinical leadership based on internal time-totreatment targets established in our clinical practice. We found several factors associated with delays to chemotherapy, including age, tumor subtype, surgical procedure, and pathology turnaround time. In patients with HR-positive tumors, Oncotype DX testing significantly increased the likelihood of UCD. When focusing on patients with higher-stage disease, only surgical procedure remained associated with timing of chemotherapy.
Although the optimal timing of chemotherapy initiation is not clearly defined, ESMO clinical practice guidelines recommend commencing treatment within 2 to 6 weeks of surgery, 15 and ASCO/NCCN recommend adjuvant chemotherapy initiation within 12 weeks of initial diagnosis for women younger than 70 years with stage II or III HR-negative breast cancer as a quality measure. 16 These recommendations are based on a combination of expert opinion and evidence from retrospective studies, because ethical imperatives prevent conducting prospective randomized trials testing the effect of purposeful delays on clinical outcomes.
Retrospective studies examining the impact of adjuvant chemotherapy wait times on survival and patient outcomes have had mixed results, which may be attributed to differences in patient populations, disease-specific factors, variability in the adjuvant treatment administered, and overall patient health status. [7] [8] [9] [10] [11] [12] 17, 18 However, emerging data suggest that, particularly for patients at higher risk of recurrence, including those with higher-stage disease, HER2-positive or TNBC subtypes, or a high proliferative rate, delayed time from surgery to chemotherapy can adversely impact outcomes. 6 9 identified that wait times greater than 49 days led to inferior overall survival among patients with rapidly proliferating tumors (P=.043). A third study, conducted by Chavez-MacGregor et al, 7 found that patients treated 91 or more days from surgery experienced worse overall survival (hazard ratio, 1.34; 95% CI, 1.17-2.00) and worse breast cancer-specific survival (hazard ratio, 1.27; 95% CI, 1.05-1.53).
With the increased complexity of breast cancer care delivery, there is concern that advances in clinical outcomes may be blunted by the challenges in delivering timely care, particularly when interdisciplinary coordination is required. Over the past decade, delays in breast cancer treatment have increased nationally, [19] [20] [21] with results from a multiinstitutional cohort study demonstrating an increase in median time from diagnosis to chemotherapy initiation from 10.8 in 2003 to 13.3 weeks in 2009. 21 Multiple factors, including age, disease-specific characteristics, type of surgical procedure, and additional testing have been found to influence this trend. [21] [22] [23] [24] [25] [26] [27] In an era of increasing use of Oncotype DX to assist with chemotherapy treatment decisions, an aging population with comorbidities needing to be addressed, and the more prevalent use of MIR, it is not surprising that wait times to adjuvant therapy continue to increase.
Although our data suggest that DF/BWCC performs reasonably well, with approximately three-quarters of patients initiating therapy within 6 weeks of surgery, an analysis of patients with a higher risk of recurrence demonstrated that 21.4% of patients (15/70) with stage III tumors, 20.2% of patients (21/104) with TNBC, and 29.5% of patients (46/156) with HER2-positive breast cancer initiated chemotherapy more than 6 weeks from LDS. These findings highlight opportunities for improvement.
Notably, we identified LDS as a significant factor associated with UCD, with patients undergoing MIR being more likely to experience delay, a finding that remained significant in patients with stage II-III disease. These results may be attributed to longer recovery time for MIR, including time for wound healing and drain removal, and the increased risk of postoperative complications. In prior work, we found that these patients also frequently experienced delays from initial consultation to breast surgery due to complexities in decision-making regarding type of reconstruction and challenges in operating room scheduling. 14 Our data raise questions about how to balance long-term quality-of-life and cosmetic outcomes with the potential impact of delays in chemotherapy on clinical outcomes. Even if surgical scheduling could be optimally streamlined, the complexity and potential delays of patient decision-making (in Reference group defined as "chemotherapy start within 28 days after last definitive surgery." Abbreviations: HR, hormone receptor; OR, odds ratio. terms of the surgical procedure), as well as wound healing requirements, will continue to make timely initiation of chemotherapy a challenge in this setting. This raises the question of whether preoperative chemotherapy should be more frequently considered in patients for whom chemotherapy is clearly indicated based on preoperative clinical staging and who desire to undergo MIR.
We also found that patients with HR-positive/ HER2-negative disease were more likely to experience delays in chemotherapy initiation compared with those with TNBC. It is possible, given the more biologically aggressive nature of TNBC, that physicians attempt to expedite processes for these patients to initiate treatment more quickly. Another explanation is that the decision to recommend chemotherapy is more straightforward with TNBC, than with HR-positive/HER2-negative tumors. In support of this hypothesis, Oncotype DX testing was ordered in 31.2% of patients with HR-positive/HER2-negative tumors. In our subsequent analyses, we found that Oncotype DX testing increased the likelihood of UCD by more than 7-fold. Vandergrift et al 21 report similar findings; in their study, Oncotype DX testing was associated with a 2.2-week increase in time to chemotherapy initiation (P<.001).
The only sociodemographic characteristic found to be associated with UCD was older age, with patients between 60 and 69 years of age being more likely to experience delays. This finding could be due to comorbidities among older patients, a factor not captured in our analyses, or due to different consideration of older patients, weighing the risks and benefits of adjuvant chemotherapy. It is also possible that providers are more apt to push for rapid treatment in younger patients; however, we were unable to assess this based on our analyses.
Our overall goal in conducting these analyses was to identify specific barriers to timely care in order to optimally focus our interventional efforts. Based on this analysis, we have initiated several efforts, including improving pathology turnaround time, expediting the communication of pathology results to providers, reducing the time from surgery to postoperative medical oncology appointment, and developing criteria for reflex ordering of Oncotype DX testing. We plan to examine the impact of these interventions on the timing of chemotherapy initiation in future studies.
Our study has several limitations. First, the relative importance of the barriers we identified may not be generalizable to other settings, particularly non-comprehensive cancer centers. Our surgeons and medical oncologists practice within the same center, and use shared electronic medical record and communication systems. The challenges of care coordination may be even greater in settings where surgery and medical oncology do not share this close relationship. Second, although we conducted chart review audits to elucidate additional factors associated with increased wait times, in half of those cases we were unable to identify a specific cause for the delayed care. Our data did not capture comorbidities of the patient cohort, which may play an important role in chemotherapy timing. Lastly, we were unable to analyze factors specifically associated with delays in TNBC and HER2-positive disease, subtypes for which the impact of delays may be greatest. Future research is warranted to uncover additional factors associated with delays, particularly in specific disease subtypes. Despite these limitations, our analysis has Reference group defined as "chemotherapy start within 28 days after LDS." Abbreviation: OR, odds ratio.
identified several areas of opportunity that are currently being addressed.
Conclusions
With the increase in wait times for breast cancer treatment, cancer centers should engage in efforts to measure and improve the timeliness of care, with a particular focus on modifiable factors within provider and institutional control.
